NCT01965600View on ClinicalTrials.gov

A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model

PHASE1TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Healthy
Interventions
DRUG

PF-06282999

Tablet, 125 mg, TID, 3 days, 1 of 2 periods

DRUG

Placebo

Tablet, 0 mg, TID, 3 days, 1 of 2 periods

OTHER

LPS

IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods

DRUG

PF-06282999

Tablet, 500 mg, BID, 3 days, 1 of 2 periods

DRUG

Placebo

Tablet, 0 mg, BID, 3 days, 1 of 2 periods

OTHER

LPS

IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods

Trial Locations (2)

27710

(Drug Shipment Address ONLY) Duke University Health Systems (DUHS) Investigational Drug Services, Durham

Duke Clinical Research Unit, Durham

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01965600 - A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model | Biotech Hunter | Biotech Hunter